摘要
目的观察听神经瘤患者Ki-67、PCNA、TGF-β1的表达情况,并分析其临床意义。方法选取接受治疗的听神经瘤患者为研究对象,同时选取同期接受手术治疗的脑外伤患者作为脑外伤组。观察两组组织中的Ki-67、PCNA、TGF-β1表达情况,比较不同临床特征听神经瘤患者的Ki-67、PCNA、TGF-β1表达情况,并分析影响听神经瘤患者Ki-67、PCNA、TGF-β1表达的因素。结果听神经瘤组患者的Ki-67、PCNA、TGF-β1阳性表达率明显高于脑外伤组(P﹤0.01);肿瘤大小﹥35 mm、生长速度≥10 mm/y、肿瘤性质为复发性患者的Ki-67、PCNA、TGF-β1阳性表达率高于肿瘤大小≤35 mm、生长速度﹤10 mm/y、肿瘤性质为原发性患者,差异均有统计学意义(P﹤0.05);而不同年龄、性别的患者Ki-67、PCNA、TGF-β1阳性表达率比较,差异均无统计学意义(P﹥0.05)。Logistic回归分析结果显示,生长速度和肿瘤性质是影响Ki-67、PCNA、TGF-β1阳性表达率的因素(P﹤0.05)。结论听神经瘤患者的Ki-67、PCNA、TGF-β1阳性表达率较高,且受瘤体生长速度和肿瘤性质的影响。
Objective To observe the expression of Ki-67, PCNA and TGF-β1 in patients with acoustic neuroma and investigate the clinical significance. Method Patients with acoustic neuroma who received treatment were recruited in the study as study subjects, while patients with traumatic brain injury that received surgical treatment during the same period were enrolled as traumatic brain injury group, the expression of Ki-67, PCNA and TGF-β1 in the two groups were observed, and were compared among patients with acoustic neuroma who had dissimilar clinical manifestations, to investigate the factors affecting the expression of Ki-67, PCNA and TGF-β1. Result The positive expression rate of Ki-67, PCNA and TGF-β1 in patients with acoustic neuroma was significantly higher than that in those with the brain injury（P〈0.01）; patients with tumor size 〉35 mm, growth rate ≥10 mm/y, and recurrent lesions had higher positive rate of Ki-67, PCNA and TGF-β1 than those with tumor size ≤35 mm, growth rate 〈10 mm/y, and primary lesions, demonstrating statistically significant differences（P〈0.05）; while there was no significant difference in the positive rate of Ki-67,PCNA and TGF-β1 regarding age and gender（P〉0.05）. Logistic regression analysis showed that growth rate and nature of tumors were the factors influencing the positive expression rate of Ki-67, PCNA and TGF-β1. Conclusion The positive rates of Ki-67, PCNA and TGF-β1 were higher in acoustic neuromas, and were associated with tumor growth rate and nature of tumor.
作者
王颖
温晓慧
辛忠海
WANG Ying;WEN Xiaohui;XIN Zhonghai(Department of ENT, Bejing Changping Hospital of Integrated Chinese and Western Medicine, Beijing 102208, China;Department of Otolaryngology-Head and Neck Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100069, China;Department of ENT, Wangjing Hospital of CACMS, Beijing 100102, China)
出处
《癌症进展》
2018年第6期743-746,共4页
Oncology Progress
